Final height in children with idiopathic growth hormone deficiency treated with recombinant human growth hormone: The Belgian experience

Thomas, Michel;Maes, Marc;Massa, G.;Bourguignon, JP.;Vandeweghe, M.;et.al.
(2001) Hormone Research — Vol. 55, n° 2, p. 88-94 (2001)

Files

42557.pdf
  • Restricted Access
  • Adobe PDF
  • 5.73 MB

Details

Authors
  • Thomas, MichelUCLouvain
    Author
  • Maes, MarcUCLouvain
    Author
  • Massa, G.
    Author
  • Bourguignon, JP.
    Author
  • De Schepper, Jean-PierreUCLouvain
    Author
  • de Zegher, FrancisUCLouvain
    Author
  • Malvaux, PaulUCLouvain
    Author
  • Vandeweghe, M.
    Author
Show more
Abstract
Background: The growth response to recombinant hGH (rhGH) treatment and final height of 61 Belgian children (32 boys) with idiopathic growth hormone deficiency (GHD) were studied. Patients/Methods: Two patient groups were compared: Group 1 with spontaneous puberty (n = 49), Group 2 with induced puberty (n = 12). The patients were treated with daily subcutaneous injections of rhGH in a dose of 0.5-0.7 IU/kg/week (0.17-0.23 mg/ kg/week) from the mean SD age of 11.9 +/- 3.1 years during 5.1 +/- 2.1 years. Results: rhGH treatment induced a doubling of the height velocity during the first year and resulted in a normalisation of height in 53 (87%) patients. Final height was -0.7 +/- 1.1 SDS, being 170.4 +/- 7.2 cm in boys and 158.0 +/- 6.4 cm in girls. Corrected for mid-parental height, final height was 0.0 +/- 1.1 SIDS. Ninety-two percent of the patients attained an adult height within the genetically determined target height range. Although height gain during puberty was smaller in the patients with induced puberty (boys: 17.1 +/- 7.0 cm vs. 27.5 +/- 6.6 cm (p < 0.005); girls: 9.6 +/- 7.4 cm vs. 22.2 +/- 6.1 cm (p < 0.005)), no differences in final height after adjustment for mid-parental height were found between patients with spontaneous or induced puberty. Conclusions: We conclude that patients with idiopathic GHD treated with rhGH administered as daily subcutaneous injections in a dose of 0.5-0.7 IU/kg/week reach their genetic growth potential, resulting in a normalisation of height in the majority of them, irrespective of spontaneous or induced puberty. Copyright (C) 2001 S. Karger AG, Basel.
Affiliations

Citations

Thomas, M., Maes, M., Massa, G., Bourguignon, JP., Craen, M., De Schepper, J.-P., de Zegher, F., Dooms, L., Du Caju, M., Francois, I., Heinrichs, C., Malvaux, P., Rooman, R., Thiry-Counson, G., & Vandeweghe, M. (2001). Final height in children with idiopathic growth hormone deficiency treated with recombinant human growth hormone: The Belgian experience. Hormone Research, 55(2), 88-94. https://doi.org/10.1159/000049976 (Original work published 2001)